Stockscreener 앱 받기
2.38
2.73%
0.00
Akebia Therapeutics Inc 주식(AKBA)의 최신 뉴스
Press Release Distribution & PR Platform - ACCESS Newswire
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - ADVFN
Lobbying Update: $45,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock - Barchart.com
US High Growth Tech Stocks to Watch in 2023 - Yahoo Finance
Akebia Therapeutics : Reports Second Quarter 2021 Financial Results and Highlights Recent Company Milestones - MarketScreener
Akebia Therapeutics gets EU positive recommendation for Xoanacyl - MSN
Akebia Therapeutics Announces Positive Opinion of European - GlobeNewswire
EMA panel endorses Akebia’s kidney disease treatment By Investing.com - Investing.com Australia
EMA panel endorses Akebia’s kidney disease treatment - Investing.com India
Akebia Therapeutics Says EMA Panel Recommends Approval of Xoanacyl for Chronic Kidney Disease Treatment - MarketScreener
Akebia Therapeutics' (AKBA) Xoanacyl Receives EMA Panel Endorsem - GuruFocus
Akebia says kidney drug endorsed in EU (AKBA:NASDAQ) - Seeking Alpha
Akebia Therapeutics EC Will Review CHMP Recommendation, Final Decision Expected In About Two Months - MarketScreener
Major Win for Akebia: EMA Committee Recommends Novel Dual-Action Kidney Disease Treatment - Stock Titan
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa - The Manila Times
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - The Manila Times
AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD) - GlobeNewswire Inc.
Jefferies Initiates Coverage of Akebia Therapeutics (AKBA) with Buy Recommendation - Nasdaq
Jefferies sets Akebia Therapeutics stock at Buy, $6 price target By Investing.com - Investing.com Canada
Jefferies Initiates Akebia Therapeutics at Buy With $6 Price Target - MarketScreener
Akebia initiated with a Buy at Jefferies - TipRanks
Analysts Love These 2 Growth Stocks That Have Over 200% Upside Potential - MSN
Piper Sandler maintains Akebia stock with $6 price target By Investing.com - Investing.com Canada
Akebia Therapeutics to Present Research at National Kidney Foundation Spring Clinical Meetings 2025 - Nasdaq
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025 - GlobeNewswire
Breakthrough Kidney Disease Treatment Data: Akebia's Vadadustat Shows Promising Results - Stock Titan
Akebia Therapeutics’ $50 Million Common Stock Offering - Global Legal Chronicle
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering - MSN
Akebia Stock Drops 28% On Pricing Of $50M Common Stock Offering - Barchart
Akebia's Valuation Looks Stretched Despite Auryxia’s Loss Of Exclusivity (NASDAQ:AKBA) - Seeking Alpha
Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday? - MSN
Akebia Therapeutics Announces $50 Mln Public Offering Of Common Stock - Nasdaq
Akebia Therapeutics Announces Public Offering Pricing - TipRanks
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benzinga
JOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Price Is Right But Growth Is Lacking After Shares Rocket 33% - Simply Wall St
Akebia Therapeutics tumbles on deep-discounted $50 mln stock sale - TradingView
Why Five Below Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket - Benzinga
Akebia Therapeutics Prices $50 Million Public Offering -March 20, 2025 at 04:19 am EDT - Marketscreener.com
Akebia Therapeutics Announces Pricing of Public Offering of Common Stock - GlobeNewswire
Akebia Therapeutics Announces Pricing Of Public Offering Of Common Stock -March 19, 2025 at 10:18 pm EDT - Marketscreener.com
Akebia Therapeutics Raises $50M: Major Stock Offering Priced at $2.00 Per Share - StockTitan
‘Buckle Up for Another Surge,’ Says Cowen About Nvidia Stock - The Globe and Mail
Akebia Therapeutics launches public stock offering By Investing.com - Investing.com South Africa
0.15%
자본화:
|
볼륨(24시간):